Biotech giant Aventis and Schering AG have settled on a valuation but are still waiting for a satisfactory bid for their joint venture company Aventis CropScience . Earlier this year, Aventis had commented that the market tended to value agrochemical companies at a seven-times multiple of its EBITDA (earnings before interest, taxes, depreciation and amortisation).